🇺🇸 FDA
Pipeline program

Phase 2; Low Dose MYOBLOC (15,000 Units)

SN-SPAS-202

Phase 3 small_molecule terminated

Quick answer

Phase 2; Low Dose MYOBLOC (15,000 Units) for Spasticity is a Phase 3 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
SUPERNUS PHARMACEUTICALS, INC.
Indication
Spasticity
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials